Fig. 2: Cytotoxicity of DoxPt against different cancer cell lines.
From: Leveraging platinum-protein interactions to overcome chemoresistance
a Heatmap comparing cytotoxicity of oxaliplatin (Ox), doxorubicin (Dox), and doxaliplatin (DoxPt) against human cancer cell lines. IC80 values are reported in SI (Table S1, Fig. S48-66). b Dose-response curves (n = 4 biological replicates) for Ox (blue), Dox (red), and DoxPt (gray) with HCT15 human colorectal adenocarcinoma cells. c Dose-response curves (n = 4 biological replicates) for Ox (blue), Dox (red), and DoxPt (gray) with MDA-MB-231 human breast adenocarcinoma cells. d Comparison of Ox, DoxPt, Dox, and a physical mixture of Dox and Ox in 1:1 molar ratio; IC80 values for parental and drug-resistant cell lines are shown in parentheses. Fold resistance was calculated as IC80-resistant ÷ IC80-parental. e Dose-response curves (n = 3 biological replicates) for Dox with MES-SA human uterine sarcoma cells (solid red line) and the doxorubicin-resistant variant MES-SA/Dx5 (dashed red line). f Dose-response curves (n = 3 biological replicates) for DoxPt with MES-SA cells (solid gray line) and MES-SA/Dx5 cells (dashed gray line). g Dose-response curves (n = 3 biological replicates) for a physical mixture of Dox and Ox (1:1 molar ratio) with MES-SA cells (solid purple line) and MES-SA/Dx5 cells (dashed purple line). For all curves, the error bars indicate standard deviation. h Comparison of activity of different platinum-containing anticancer agents against MES-SA and MES-SA/Dx5 cells. Fold resistance was calculated as IC80-resistant ÷ IC80-parental. Data in panels (b, c, e, f) and (g) are presented as mean values ± SD. Source data are provided as a file.
